Literature DB >> 18572306

A pilot trial with modified Atkins' diet in adult patients with refractory epilepsy.

Evelien Carrette1, Kristl Vonck, Veerle de Herdt, Isabelle Dewaele, Robrecht Raedt, Lut Goossens, Michel Van Zandijcke, Wytse Wadman, Vijay Thadani, Paul Boon.   

Abstract

OBJECTIVES: At Ghent University Hospital, the feasibility and efficacy of the modified Atkins' diet was evaluated in adult patients with refractory epilepsy. The Atkins' diet restricts carbohydrate intake and was originally designed for weight loss. PATIENTS AND METHODS: During a 6-month trial period, a carbohydrate restriction of 20 g/day was in place. During a 36 h hospital admission, patients were instructed about the diet. Patients underwent clinical neurological testing, EEG, ECG, blood and urine analyses and mood evaluation before and during the trial. Seizure frequency and side effects were recorded in seizure diaries and followed up at monthly clinic visits.
RESULTS: Eight patients were included in the study. Three out of eight patients followed the diet for 6 months. One out of three patients showed a >50% seizure reduction, 1/3>30%, and 1/3<30%. Side effects such as constipation and diarrhoea were mild and occurred mainly during the initial week of the diet. Patients reported improved concentration and well being. This was confirmed by improved scores on the Beck Depression Inventory Scale.
CONCLUSION: This pilot study shows that the modified Atkins' diet is feasible in an adult population, and that seizure frequency reduction is possible. The results need to be confirmed in larger prospective, controlled studies with comparison groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572306     DOI: 10.1016/j.clineuro.2008.05.003

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  9 in total

Review 1.  Dietary therapies for epilepsy: future research.

Authors:  Sudha K Kessler; Elizabeth G Neal; Carol S Camfield; Eric H Kossoff
Journal:  Epilepsy Behav       Date:  2011-03-26       Impact factor: 2.937

2.  The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit.

Authors:  Mackenzie C Cervenka; Adam L Hartman; Arun Venkatesan; Romergryko G Geocadin; Eric H Kossoff
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

Review 3.  Ketogenic Diets for Adult Neurological Disorders.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

4.  Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis.

Authors:  Fang Ye; Xiao-Jia Li; Wan-Lin Jiang; Hong-Bin Sun; Jie Liu
Journal:  J Clin Neurol       Date:  2015-01-02       Impact factor: 3.077

5.  Use of Remote Monitoring by E-mail for Long-Term Management of the Classic Ketogenic Diet.

Authors:  Cinzia Ferraris; Monica Guglielmetti; Elisa Tamagni; Claudia Trentani; Valentina De Giorgis; Ludovica Pasca; Costanza Varesio; Ottavia Eleonora Ferraro; Anna Tagliabue
Journal:  Nutrients       Date:  2020-06-19       Impact factor: 5.717

Review 6.  The role for ketogenic diets in epilepsy and status epilepticus in adults.

Authors:  Tanya J Williams; Mackenzie C Cervenka
Journal:  Clin Neurophysiol Pract       Date:  2017-07-01

Review 7.  The modified atkins diet in refractory epilepsy.

Authors:  Suvasini Sharma; Puneet Jain
Journal:  Epilepsy Res Treat       Date:  2014-01-30

8.  Modified Atkins diet in adult with refractory epilepsy: A controlled randomized clinical trial.

Authors:  Mohammad Zare; Ali Asghar Okhovat; Ahmad Esmaillzadeh; Jafar Mehvari; Mohammad Reza Najafi; Mohammad Saadatnia
Journal:  Iran J Neurol       Date:  2017-04-04

Review 9.  Ketogenic diet for treatment of intractable epilepsy in adults: A meta-analysis of observational studies.

Authors:  Hongyan Liu; Yi Yang; Yunbing Wang; Hong Tang; Fan Zhang; Yong Zhang; Yong Zhao
Journal:  Epilepsia Open       Date:  2018-02-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.